Long-term survival and functional outcomes of critically ill patients with hematologic malignancies : a Canadian multicenter prospective study
© 2024. Crown..
PURPOSE: Patients with hematologic malignancy (HM) commonly develop critical illness. Their long-term survival and functional outcomes have not been well described.
METHODS: We conducted a prospective, observational study of HM patients admitted to seven Canadian intensive care units (ICUs) (2018-2020). We followed survivors at 7 days, 6 months and 12 months following ICU discharge. The primary outcome was 12-month survival. We evaluated functional outcomes at 6 and 12 months using the functional independent measure (FIM) and short form (SF)-36 as well as variables associated with 12-month survival.
RESULTS: We enrolled 414 patients including 35% women. The median age was 61 (interquartile range, IQR: 52-69), median Sequential Organ Failure Assessment (SOFA) score was 9 (IQR: 6-12), and 22% had moderate-severe frailty (clinical frailty scale [CFS] ≥ 6). 51% had acute leukemia, 38% lymphoma/multiple myeloma, and 40% had received a hematopoietic stem cell transplant (HCT). The most common reasons for ICU admission were acute respiratory failure (50%) and sepsis (40%). Overall, 203 (49%) were alive 7 days post-ICU discharge (ICU survivors). Twelve-month survival of the entire cohort was 21% (43% across ICU survivors). The proportion of survivors with moderate-severe frailty was 42% (at 7 days), 14% (6 months), and 8% (12 months). Median FIM at 7 days was 80 (IQR: 50-109). Physical function, pain, social function, mental health, and emotional well-being were below age- and sex-matched population scores at 6 and 12 months. Frailty, allogeneic HCT, kidney injury, and cardiac complications during ICU were associated with lower 12- month survival.
CONCLUSIONS: 49% of all HM patients were alive at 7 days post-ICU discharge, and 21% at 12 months. Survival varied based upon hematologic diagnosis and frailty status. Survivors had important functional disability and impairment in emotional, physical, and general well-being.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Intensive care medicine - 50(2024), 4 vom: 11. Apr., Seite 561-572 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munshi, Laveena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hematologic malignancy |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00134-024-07349-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369561309 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369561309 | ||
| 003 | DE-627 | ||
| 005 | 20240416232655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00134-024-07349-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM369561309 | ||
| 035 | |a (NLM)38466402 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munshi, Laveena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term survival and functional outcomes of critically ill patients with hematologic malignancies |b a Canadian multicenter prospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. Crown. | ||
| 520 | |a PURPOSE: Patients with hematologic malignancy (HM) commonly develop critical illness. Their long-term survival and functional outcomes have not been well described | ||
| 520 | |a METHODS: We conducted a prospective, observational study of HM patients admitted to seven Canadian intensive care units (ICUs) (2018-2020). We followed survivors at 7 days, 6 months and 12 months following ICU discharge. The primary outcome was 12-month survival. We evaluated functional outcomes at 6 and 12 months using the functional independent measure (FIM) and short form (SF)-36 as well as variables associated with 12-month survival | ||
| 520 | |a RESULTS: We enrolled 414 patients including 35% women. The median age was 61 (interquartile range, IQR: 52-69), median Sequential Organ Failure Assessment (SOFA) score was 9 (IQR: 6-12), and 22% had moderate-severe frailty (clinical frailty scale [CFS] ≥ 6). 51% had acute leukemia, 38% lymphoma/multiple myeloma, and 40% had received a hematopoietic stem cell transplant (HCT). The most common reasons for ICU admission were acute respiratory failure (50%) and sepsis (40%). Overall, 203 (49%) were alive 7 days post-ICU discharge (ICU survivors). Twelve-month survival of the entire cohort was 21% (43% across ICU survivors). The proportion of survivors with moderate-severe frailty was 42% (at 7 days), 14% (6 months), and 8% (12 months). Median FIM at 7 days was 80 (IQR: 50-109). Physical function, pain, social function, mental health, and emotional well-being were below age- and sex-matched population scores at 6 and 12 months. Frailty, allogeneic HCT, kidney injury, and cardiac complications during ICU were associated with lower 12- month survival | ||
| 520 | |a CONCLUSIONS: 49% of all HM patients were alive at 7 days post-ICU discharge, and 21% at 12 months. Survival varied based upon hematologic diagnosis and frailty status. Survivors had important functional disability and impairment in emotional, physical, and general well-being | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hematologic malignancy | |
| 650 | 4 | |a Immunocompromised | |
| 650 | 4 | |a Long-term outcomes | |
| 700 | 1 | |a Dumas, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Rochwerg, Bram |e verfasserin |4 aut | |
| 700 | 1 | |a Shoukat, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Detsky, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Fergusson, Dean A |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreyro, Bruno L |e verfasserin |4 aut | |
| 700 | 1 | |a Heffernan, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Herridge, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Magder, Sheldon |e verfasserin |4 aut | |
| 700 | 1 | |a Minden, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Qureshi, Salman |e verfasserin |4 aut | |
| 700 | 1 | |a Schimmer, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Thyagu, Santhosh |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Han Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Sangeeta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d 1993 |g 50(2024), 4 vom: 11. Apr., Seite 561-572 |w (DE-627)NLM000234818 |x 1432-1238 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:4 |g day:11 |g month:04 |g pages:561-572 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00134-024-07349-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 4 |b 11 |c 04 |h 561-572 | ||